Adalimumab (n=40)

Non-switchers

Etanercept (n=33)

Switchers

Golimumab (n=9)

Golimumab (n=6)

Infliximab (n=29)

Infliximab (n=68)

Adalimumab (n=30)

Etanercept (n=4)

Golimumab (n=14)

Golimumab (n=3)

Adalimumab (n=1)

Golimumab (n=3)

Infliximab (n=5)

Golimumab (n=1)

Golimumab (n=1)

Golimumab (n=1)

Adalimumab (n=2)

Infliximab (n=1)

Adalimumab (n=27)

Golimumab (n=8)

Etanercept (n=4)

Adalimumab (n=1)

Golimumab (n=2)

Etanercept (n=2)

Figure 1.
<table>
<thead>
<tr>
<th></th>
<th>Non-switchers N=98</th>
<th>Switchers N=77</th>
<th>significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean±SD)</td>
<td>38.8±11.2</td>
<td>42.5±12.6</td>
<td>0.049</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>22 (22.4%)</td>
<td>20 (26.3%)</td>
<td>N.S.</td>
</tr>
<tr>
<td>Disease duration (mean±SD)</td>
<td>8.72±8.30</td>
<td>8.63±9.02</td>
<td>N.S.</td>
</tr>
<tr>
<td>BASDAI (mean±SD)</td>
<td>7.07±1.30</td>
<td>7.11±1.19</td>
<td>N.S.</td>
</tr>
</tbody>
</table>

Age: age of the patients at the beginning of first TNF inhibitor
Disease duration: duration between the date of diagnosis and start of first TNF blocker
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index

Table 1.
Figure 2.

BASDAI values to first TNFi among non-switchers

BASDAI values to first TNFi among switchers

BASDAI values to second TNFi among switchers
<table>
<thead>
<tr>
<th>Cause of switching</th>
<th>adalimumab</th>
<th>etanercept</th>
<th>golimumab</th>
<th>infliximab</th>
<th>total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inefficacy</td>
<td>7 (70.0%)</td>
<td>17 (68.0%)</td>
<td>2 (66.7%)</td>
<td>16 (41.0%)</td>
<td>42 (54.5%)</td>
</tr>
<tr>
<td>Side effect</td>
<td>1 (10.0%)</td>
<td>3 (12.0%)</td>
<td>1 (33.3%)</td>
<td>18 (46.2%)</td>
<td>23 (29.9%)</td>
</tr>
<tr>
<td>Patient’s request</td>
<td>1 (10.0%)</td>
<td>0</td>
<td>0</td>
<td>5 (12.8%)</td>
<td>6 (7.8%)</td>
</tr>
<tr>
<td>Extra-articular manifestation</td>
<td>1 (10.0%)</td>
<td>5 (20.0%)</td>
<td>0</td>
<td>0</td>
<td>6 (7.8%)</td>
</tr>
</tbody>
</table>

Table 2.
Figure 3.

Drug survival of first TNFi

Drug survival of second TNFi

log-rank test

p=0.066

log-rank test

p=0.108